Camp4 Therapeutics (CAMP) grants director 28,000 stock options

Rhea-AI Filing Summary

Camp4 Therapeutics Corp director Richard A. Young reported receiving a compensation grant of stock options. He was awarded options to buy 28,000 shares of common stock at an exercise price of $4.34 per share, expiring on June 9, 2036.

The options vest in full on the earlier of the first anniversary of the grant date or the company’s next annual meeting of stockholders, as long as he continues serving the company through that date. After this grant, he holds options for 28,000 shares directly.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Young Richard A

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	28,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 28,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 28,000 options Exercise price: $4.34 per share Post-grant option holdings: 28,000 options +1 more

4 metrics

Option grant size 28,000 options Stock Option (Right to Buy) granted to director

Exercise price $4.34 per share Conversion or exercise price of options

Post-grant option holdings 28,000 options Total derivative shares following transaction

Expiration date June 9, 2036 Option expiration date

Key Terms

Stock Option (Right to Buy), exercise price, vest in their entirety, annual meeting of stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

exercise price financial

"conversion_or_exercise_price: 4.3400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in their entirety financial

"The shares underlying the option vest in their entirety on the earlier of the first anniversary"

annual meeting of stockholders regulatory

"earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Young Richard A

(Last) (First) (Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$4.34	06/10/2026		A		28,000		(1)	06/09/2036	Common Stock	28,000	$0	28,000	D

Explanation of Responses:

1. The shares underlying the option vest in their entirety on the earlier of the first anniversary of the grant date or the date of the issuer's next annual meeting of stockholders, subject to continued service to the Company through the applicable vesting date.

Remarks:

	/s/ Josh Mandel-Brehm, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Camp4 Therapeutics (CAMP) director Richard A. Young report on this Form 4?

Director Richard A. Young reported receiving a grant of stock options. The award covers 28,000 shares of Camp4 Therapeutics common stock and is structured as a compensation grant, not an open-market purchase, according to the Form 4 details and accompanying footnote.

How many Camp4 Therapeutics (CAMP) shares are covered by the new stock options?

The new stock option grant covers 28,000 shares of Camp4 Therapeutics common stock. These options give the director the right to buy those shares in the future at a preset exercise price described in the Form 4 filing.

What is the exercise price of the Camp4 Therapeutics (CAMP) options granted to the director?

The stock options granted to the director have an exercise price of $4.34 per share. This means he can later purchase up to 28,000 shares of Camp4 Therapeutics common stock at $4.34, regardless of the market price at exercise time.

When do the Camp4 Therapeutics (CAMP) director’s new options vest?

The options vest in full on the earlier of the first anniversary of the grant date or the date of Camp4 Therapeutics’ next annual meeting of stockholders. Vesting is conditioned on the director’s continued service to the company through that vesting date.

When do the newly granted Camp4 Therapeutics (CAMP) stock options expire?

The stock options granted to the director expire on June 9, 2036. After that expiration date, the right to buy the 28,000 Camp4 Therapeutics common shares at the $4.34 exercise price will lapse and can no longer be exercised.

How many Camp4 Therapeutics (CAMP) options does the director hold after this transaction?

Following this grant, the director holds options covering 28,000 shares of Camp4 Therapeutics common stock. The Form 4 shows this as his total derivative position after the transaction, all held as a direct ownership interest.